Drugs / LLG783
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03194776 | Sep 2017 → Sep 2018 | peripheral arterial disease | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LLG783 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03194776 ↗ |
| Route | Intravenous | “LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.” NCT03194776 ↗ |
| Route | Subcutaneous | “LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.” NCT03194776 ↗ |